



Corrigendum: The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis *via* Modulating Multiple Signaling Pathways in Mice

OPEN ACCESS

Edited and reviewed by:

Salvatore Salomone,
University of Catania, Italy

*Correspondence:

Zhaofang Bai
baizf2008@hotmail.com
Xiaoyan Zhan
xyzhan123@163.com
Xiaohu Xiao
pharmacy_302@126.com

†These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology

Received: 16 September 2021

Accepted: 21 September 2021

Published: 07 September 2021

Citation:

Ai Y, Shi W, Zuo X, Sun X, Chen Y,
Wang Z, Li R, Song X, Dai W, Mu W,
Ding K, Li Z, Li Q, Xiao X, Zhan X and
Bai Z (2021) Corrigendum: The
Combination of Schisandrol B and
Wedelolactone Synergistically
Reverses Hepatic Fibrosis *via*
Modulating Multiple Signaling
Pathways in Mice.
Front. Pharmacol. 12:777914.
doi: 10.3389/fphar.2021.777914

Yongqiang Ai^{1†}, Wei Shi^{1†}, Xiaobin Zuo^{1†}, Xiaoming Sun^{1†}, Yuanyuan Chen¹, Zhilei Wang¹,
Ruisheng Li², Xueai Song³, Wenzhang Dai¹, Wenqing Mu¹, Kaixin Ding¹, Zhiyong Li¹,
Qiang Li¹, Xiaohu Xiao^{1,3*}, Xiaoyan Zhan^{1,3*} and Zhaofang Bai^{1,3*}

¹Department of Hepatology, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China, ²Research Center for Clinical and Translational Medicine, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China, ³China Military Institute of Chinese Materia, The Fifth Medical Centre, Chinese PLA General Hospital, Beijing, China

Keywords: schisandrol B, wedelolactone, hepatic fibrosis, combined pharmacotherapy, TGF- β 1/Smads signaling pathway

A Corrigendum on

The Combination of Schisandrol B and Wedelolactone Synergistically Reverses Hepatic Fibrosis *via* Modulating Multiple Signaling Pathways in Mice

by Ai, Y., Shi, W., Zuo, X., Sun, X., Chen, Y., Wang, Z., Li, R., Song, X., Dai, W., Mu, W., Ding, K., Li, Z., Li, Q., Xiao, X., Zhan, X., Bai, Z. (2021). *Front. Pharmacol.* 12:655531. doi: 10.3389/fphar.2021.655531

In the original article, there was a mistake in **Figure 5** as published. The symbols (*, **, ***, ns) of statistic differences in **Figures 5B–F** were wrongly labeled. The wrongly labeled **Figure 5** was uploaded by accident when submitting the corrections of proof. The corrected **Figure 5** appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Copyright © 2021 Ai, Shi, Zuo, Sun, Chen, Wang, Li, Song, Dai, Mu, Ding, Li, Li, Xiao, Zhan and Bai. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

